632 - Epidemiology projection trends for metastatic colorectal cancer (mCRC) patients receiving second line (2L) therapy in EU and US
|Date||28 September 2012|
|Event||ESMO Congress 2012|
|Topics|| Cancer Aetiology, Epidemiology, Prevention
O. Moulard1, J. Mehta2, S. Naoshy2, R. Olivares1, S.U. Iqbal2, I. Chau3
Worldwide, CRC is the third most common cancer in men (663,000 cases, 10% of the total) and second in women (571,000 cases, 9.4% of the total) (IARC 2008). Due to demographic expansion and an ageing population, the annual number of newly diagnosed and treated CRC cases is expected to increase in Western countries. Hence, epidemiology projection estimates by line of therapy are needed to support clinical, economic and resource planning.Methods
Epidemiological data was obtained using the CancerMPact® database (accessed Oct 2011), which includes line of therapy estimations through the US National Oncology Data Alliance and survey of a representative physician sample. Data was grouped by stage at diagnosis and stage IV refers to metastatic patients.Results
From 2010-2020, the distribution of mCRC patients receiving 2L differs by country in EU. The highest number of treated patients is in Germany, followed by Italy and UK. Among all treated mCRC patients, about 42% of patients in EU and 45% of patients in US will go on to 2L. By 2020, the percentage of patients receiving 1L and 2L will increase by about 15% across US and EU. Over a 10 year period, the number of treated patients for each line of therapy will increase by 19%, 11%, 15%, 20%, and 14% for France, Germany, Italy, Spain and UK, respectively. The table below refers to the number of metastatic patients by line of therapy.Conclusions
Despite improvement in survival rates, approximately half of patients in US and EU who receive 1L go on to 2L. In addition to survey data, real world data and disease based registries can help validate these projection estimates. The projected increase in mCRC patients by 10-20% across the EU has implications for disease management and health resource planning in oncology.
|Year||Line||Number of patients|
|Total stage IV*||19344||36313||25408||13432||23372||117869||60703|
|Total stage IV*||22947||39931||29361||16194||26733||135166||69391|
* a patient may receive multiple lines of therapy in a given year Source: CancerMPact® Kantar Health (www.cancermpact.com)Disclosure
O. Moulard: I am an employee of Sanofi.
J. Mehta: I am an employee of Sanofi.
S. Naoshy: I am an employee of Sanofi.
R. Olivares: I am an employee of Sanofi.
S.U. Iqbal: I am an employee of Sanofi.
All other authors have declared no conflicts of interest.